Alpha-lipoic acid for PCOS: what the evidence says

1. What is alpha-lipoic acid?

Alpha-lipoic acid is a sulfur-containing compound involved in the way cells make and use energy. The body produces small amounts of it, and it is also sold as a dietary supplement.

ALA is often described as an antioxidant, but that is only one part of the picture. In metabolic research, it draws interest because it may affect how cells handle glucose, how insulin signals are passed along, and how mitochondria — the tiny energy-producing structures inside cells — function.

That is why researchers have studied it in polycystic ovary syndrome, or PCOS. PCOS is not only a reproductive condition. Many women with PCOS also have insulin resistance, which means the body has to release more insulin to keep blood sugar in range. Higher insulin can worsen several PCOS features, including androgen excess and irregular ovulation, although not every woman with PCOS has the same metabolic pattern.

2. How ALA might work in PCOS

The main theory is metabolic. ALA may help muscle, fat, and liver cells respond better to insulin. Mechanistic reviews suggest several possible pathways: activation of AMPK, movement of GLUT4 glucose transporters to the cell surface, changes in PI3K/Akt insulin signalling, improved mitochondrial function, and reduced oxidative or inflammatory signalling.

Put more simply, ALA may help cells take up and use glucose more efficiently. It may also influence how the liver clears insulin from the bloodstream. That fits with the PCOS studies, where the stronger effects tend to show up in glucose and insulin-resistance markers rather than reproductive hormones.

This distinction is important. A plausible mechanism does not mean a supplement has been proven to improve symptoms someone can feel, such as cycle regularity, acne, unwanted hair growth, fertility, or long-term diabetes risk. It only explains why ALA is worth studying.

3. What the clinical evidence says

The best broad summary so far is a 2024 systematic review and meta-analysis of seven randomized trials in women with PCOS. Doses ranged from 600 to 1,800 mg per day, and study durations ranged from 6 to 25 weeks.

The review found that ALA was associated with lower fasting blood sugar and lower HOMA-IR. HOMA-IR is a calculation based on fasting glucose and insulin, used as a rough marker of insulin resistance. The fasting glucose finding had moderate certainty. The HOMA-IR finding looked large, but it was less secure because the studies differed a lot from one another.

The same review did not find significant pooled effects on BMI, fasting insulin, estrogen, FSH, LH, testosterone, LDL, HDL, triglycerides, total cholesterol, malondialdehyde, or total antioxidant capacity. In other words, the overall trial picture is not “ALA improves PCOS” in a broad sense. It is more specific: ALA may improve some glucose and insulin-resistance markers in some women. This also means broader weight benefits in PCOS remain unproven.

A few smaller studies add useful context. In a tiny uncontrolled 2010 study, six lean, nondiabetic women with PCOS took controlled-release ALA 600 mg twice daily for 16 weeks. Insulin sensitivity measured by the euglycemic clamp — a precise research method — improved by 13.5%. Triglycerides also fell, and two women not using oral contraception had more menstrual cycles during treatment. But with only six participants and no placebo group, this can only be treated as hypothesis-generating.

In a 2018 study of 32 obese women with PCOS, ALA 400 mg daily for 12 weeks was linked with decreases in insulin, glucose, BMI, and HOMA index. Reproductive hormones such as LH, FSH, and androstenedione did not materially change. A 2024 retrospective study in overweight or obese women again suggested improved insulin sensitivity and lower liver enzymes, with a stronger response in women with a family history of diabetes.

Taken together, these studies point toward a metabolic effect, possibly strongest in insulin-resistant PCOS or in women with a diabetes-risk phenotype. They do not yet show a reliable endocrine effect, such as lowering testosterone or normalizing reproductive hormones.

4. Has ALA been studied alone or mainly with other treatments?

Both — but much of the more clinically interesting fertility research has tested ALA as an add-on.

ALA-alone studies do exist, including the small controlled-release study and the 400 mg daily studies in obese or overweight women. These usually focus on insulin sensitivity, glucose handling, triglycerides, liver enzymes, and related metabolic outcomes.

Combination studies are common. ALA has been paired with d-chiro-inositol, myo-inositol, metformin, letrozole, clomiphene-based regimens, pentoxifylline, and assisted reproduction protocols. That makes the results harder to interpret. If cycles improve during a combined myo-inositol plus ALA programme, it is not possible to say ALA caused the improvement unless the study is designed to isolate its effect.

For example, a 2019 study of d-chiro-inositol plus ALA reported improved menstrual cycle length in many women and restored ovulation in 40%. But it was a combination product. A 2020 retrospective study comparing ALA with two different myo-inositol doses found better menstrual regularity, especially with the higher myo-inositol dose. The authors noted that the difference appeared related to the inositol dose rather than ALA itself.

Fertility trials are especially relevant, but they are still not definitive. In a 2022 randomized study of women with PCOS undergoing ICSI, metformin plus ALA improved mature oocyte count, fertilization rate, and good-quality embryo number compared with metformin alone. It also improved some glucose, hormone, and oxidative-stress markers. But biochemical pregnancy, clinical pregnancy, miscarriage, and live birth were not significantly different.

A larger randomized trial published on August 19, 2026 tested ALA 1,800 mg daily added to letrozole and lifestyle modification in 151 infertile women with PCOS. Ovulation per cycle and pregnancy per cycle were higher with ALA than with letrozole alone. This is an important step forward because letrozole is already a preferred first-line ovulation-induction medicine in PCOS. Still, the study tested ALA as an add-on, not as monotherapy. It also needs independent replication and live-birth confirmation before it can be treated as established care.

Another randomized open-label study in clomiphene-resistant PCOS found that adding ALA to clomiphene produced numerically higher ovulation and pregnancy rates than clomiphene alone, but the strongest results came from pentoxifylline-containing arms. Pentoxifylline plus ALA was not clearly better than pentoxifylline alone. That tempers the idea that ALA is the decisive fertility ingredient.

5. Practical considerations

In PCOS trials, ALA doses have commonly ranged from 400 mg to 1,800 mg per day. Some studies used 400 mg daily; others used 600 mg twice daily or 1,800 mg daily. Durations were usually short, often around 6 to 16 weeks, with the 2024 review including studies up to 25 weeks.

There is no established PCOS dose. Higher doses used in fertility studies should not be casually copied without medical guidance, especially when ALA is combined with glucose-lowering medication, ovulation-induction drugs, or fertility treatment.

The 2023 International Evidence-based Guideline for PCOS recommends lifestyle intervention for all women with PCOS. It recommends metformin for metabolic indications, especially in adults with BMI of 25 kg/m² or higher, and letrozole as the preferred first-line pharmacological option for infertility due to anovulation. ALA is not included as standard PCOS therapy.

The practical takeaway is simple: ALA may be a research-backed adjunct in selected metabolic or fertility contexts, but it should not replace lifestyle care, metformin when indicated, letrozole when appropriate, or individualised medical treatment.

6. Safety

Short-term studies suggest ALA is usually reasonably well tolerated. Common side effects at higher doses include abdominal discomfort, heartburn, nausea, constipation or diarrhoea, dizziness, and headache.

ALA is sold as a dietary supplement and is not approved by the FDA to treat PCOS or any medical disease. That does not mean it is useless, but it does mean supplement quality, dose, and claims can vary.

There are also less common but more serious concerns. Very high overdose exposures have been linked with confusion, seizures, lactic acidosis, rhabdomyolysis, coma, organ failure, and death. These are rare and not typical of conventional supplement dosing, but they are a reminder that high-dose unsupervised use should not be treated as harmless.

A specific safety issue is insulin autoimmune syndrome, a rare condition in which the immune system produces antibodies against insulin, sometimes causing episodes of abnormal blood sugar. A 2021 EFSA scientific opinion concluded that the risk from oral ALA cannot be precisely quantified and that no safe intake threshold could be confidently identified from the available evidence.

Anyone using insulin, metformin, GLP-1 medicines, sulfonylureas, or other glucose-lowering therapies should be cautious because ALA may interact with glucose control. Women trying to conceive, undergoing fertility treatment, pregnant, breastfeeding, or managing thyroid or autoimmune disease should discuss ALA with a clinician first.